PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression
Publication
, Conference
Secord, AA; Lewin, S; Murphy, C; Method, M
Published in: GYNECOLOGIC ONCOLOGY
2022
Duke Scholars
Published In
GYNECOLOGIC ONCOLOGY
EISSN
1095-6859
ISSN
0090-8258
Publication Date
2022
Volume
166
Start / End Page
S157 / S158
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Secord, A. A., Lewin, S., Murphy, C., & Method, M. (2022). PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression. In GYNECOLOGIC ONCOLOGY (Vol. 166, pp. S157–S158).
Secord, Angeles Alvarez, Sharyn Lewin, Conleth Murphy, and Michael Method. “PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression.” In GYNECOLOGIC ONCOLOGY, 166:S157–58, 2022.
Secord AA, Lewin S, Murphy C, Method M. PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression. In: GYNECOLOGIC ONCOLOGY. 2022. p. S157–8.
Secord, Angeles Alvarez, et al. “PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression.” GYNECOLOGIC ONCOLOGY, vol. 166, 2022, pp. S157–58.
Secord AA, Lewin S, Murphy C, Method M. PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression. GYNECOLOGIC ONCOLOGY. 2022. p. S157–S158.
Published In
GYNECOLOGIC ONCOLOGY
EISSN
1095-6859
ISSN
0090-8258
Publication Date
2022
Volume
166
Start / End Page
S157 / S158
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis